Search

Your search keyword '"Pezzullo L"' showing total 490 results
Start Over Author "Pezzullo L"
490 results on '"Pezzullo L"'

1. Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients

Author

Besharat, Z. M., Trocchianesi, S., Verrienti, A., Ciampi, R., Cantara, S., Romei, C., Sabato, C., Noviello, T. M. R., Po, A., Citarella, A., Caruso, F. P., Panariello, I., Gianno, F., Carpino, G., Gaudio, E., Chiacchiarini, M., Masuelli, L., Sponziello, M., Pecce, V., Ramone, T., Maino, F., Dotta, F., Ceccarelli, M., Pezzullo, L., Durante, C., Castagna, M. G., Elisei, R., and Ferretti, E.

Published
2023
Full Text
View/download PDF

2. Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients

Author

Besharat, Z. M., Trocchianesi, S., Verrienti, A., Ciampi, R., Cantara, S., Romei, C., Sabato, C., Noviello, T. M. R., Po, A., Citarella, A., Caruso, F. P., Panariello, I., Gianno, F., Carpino, G., Gaudio, E., Chiacchiarini, M., Masuelli, L., Sponziello, M., Pecce, V., Ramone, T., Maino, F., Dotta, F., Ceccarelli, M., Pezzullo, L., Durante, C., Castagna, M. G., Elisei, R., and Ferretti, E.

Published
2024
Full Text
View/download PDF

4. Correction: Circulating miR‑26b‑5p and miR‑451a as diagnostic biomarkers in medullary thyroid carcinoma patients

Author

Besharat, Z. M., primary, Trocchianesi, S., additional, Verrienti, A., additional, Ciampi, R., additional, Cantara, S., additional, Romei, C., additional, Sabato, C., additional, Noviello, T. M. R., additional, Po, A., additional, Citarella, A., additional, Caruso, F. P., additional, Panariello, I., additional, Gianno, F., additional, Carpino, G., additional, Gaudio, E., additional, Chiacchiarini, M., additional, Masuelli, L., additional, Sponziello, M., additional, Pecce, V., additional, Ramone, T., additional, Maino, F., additional, Dotta, F., additional, Ceccarelli, M., additional, Pezzullo, L., additional, Durante, C., additional, Castagna, M. G., additional, Elisei, R., additional, and Ferretti, E., additional

Published
2023
Full Text
View/download PDF

5. Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB)

Author

Rosato, L., De Crea, C., Bellantone, R., Brandi, M. L., De Toma, G., Filetti, S., Miccoli, P., Pacini, F., Pelizzo, M. R., Pontecorvi, A., Avenia, N., De Pasquale, L., Chiofalo, M. G., Gurrado, A., Innaro, N., La Valle, G., Lombardi, C. P., Marini, P. L., Mondini, G., Mullineris, B., Pezzullo, L., Raffaelli, M., Testini, M., and De Palma, M.

Published
2016
Full Text
View/download PDF

6. Impact of the COVID-19 pandemic on surgery for thyroid cancer in Italy: nationwide retrospective study

Author

Medas, F., Ansaldo, G. L., Avenia, N., Basili, G., Bononi, M., Bove, A., Carcoforo, P., Casaril, A., Cavallaro, G., Conzo, G., De Pasquale, L., Del Rio, P., Dionigi, G., Dobrinja, C., Docimo, G., Graceffa, G., Iacobone, M., Innaro, N., Lombardi, C. P., Novelli, G., Palestini, N., Pedicini, F., Perigli, G., Pezzolla, A., Pezzullo, L., Scerrino, G., Spiezia, S., Testini, M., Calo, P. G., Anedda, G., Antonelli, G., Arrigoni, G., Badii, B., Bonati, E., Boniardi, M., Bulfamante, A. M., Candalise, V., Cangiano, A., Canu, G. L., Cappellacci, F., Caracciolo, A., Caruso, E., Casal Ide, E., Chiappini, A., Chiofalo, M. G., Cipolla, C., Costigliola, L., Cozzani, F., Crocco, A., Crocetti, D., De Manzini, N., DI Gioia, A., DI Resta, V., Eramo, R., Erdas, E., Ferriolo, S., Filardo, M., Filograna Pignatelli, M., Gervasi, R., Giudici, F., Gordini, L., Gurrado, A., Impellizzeri, H., Inama, M., Koleva Radica, M., Laforgia, R., Lattarulo, S., Loderer, T., Lucchini, R., Mascioli, F., Marcellinaro, R., Menditto, R., Melfa, G., Minuto, M., Misso, C., Offi, C., Orlando, G., Ossola, P., Pagetta, C., Pasculli, A., Patrone, R., Pauna, I., Pennetti Pennella, F., Pietrasanta, D., Pino, A., Pinto, V. L., Piras, S., Polistena, A., Portinari, M., Reina, S., Rotolo, G., Russo, G., Scalise, E., Sgaramella, L. I., Sibilla, M. G., Spinelli, S., Spoletini, D., Curto, L. S., Tascone, M., Torresan, F., Varaldo, E., Viviani, E., Zucca, A., Medas, F, Ansaldo, G L, Avenia, N, Basili, G, Bononi, M, Bove, A, Carcoforo, P, Casaril, A, Cavallaro, G, Conzo, G, De Pasquale, L, Del Rio, P, Dionigi, G, Dobrinja, C, Docimo, G, Graceffa, G, Iacobone, M, Innaro, N, Lombardi, C P, Novelli, G, Palestini, N, Pedicini, F, Perigli, G, Pezzolla, A, Pezzullo, L, Scerrino, G, Spiezia, S, Testini, M, Calò, P G, Cipolla C, Medas, F., Ansaldo, G. L., Avenia, N., Basili, G., Bononi, M., Bove, A., Carcoforo, P., Casaril, A., Cavallaro, G., Conzo, G., De Pasquale, L., Del Rio, P., Dionigi, G., Dobrinja, C., Docimo, G., Graceffa, G., Iacobone, M., Innaro, N., Lombardi, C. P., Novelli, G., Palestini, N., Pedicini, F., Perigli, G., Pezzolla, A., Pezzullo, L., Scerrino, G., Spiezia, S., Testini, M., Calo, P. G., Anedda, G., Antonelli, G., Arrigoni, G., Badii, B., Bonati, E., Boniardi, M., Bulfamante, A. M., Candalise, V., Cangiano, A., Canu, G. L., Cappellacci, F., Caracciolo, A., Caruso, E., Casal Ide, E., Chiappini, A., Chiofalo, M. G., Cipolla, C., Costigliola, L., Cozzani, F., Crocco, A., Crocetti, D., De Manzini, N., DI Gioia, A., DI Resta, V., Eramo, R., Erdas, E., Ferriolo, S., Filardo, M., Filograna Pignatelli, M., Gervasi, R., Giudici, F., Gordini, L., Gurrado, A., Impellizzeri, H., Inama, M., Koleva Radica, M., Laforgia, R., Lattarulo, S., Loderer, T., Lucchini, R., Mascioli, F., Marcellinaro, R., Menditto, R., Melfa, G., Minuto, M., Misso, C., Offi, C., Orlando, G., Ossola, P., Pagetta, C., Pasculli, A., Patrone, R., Pauna, I., Pennetti Pennella, F., Pietrasanta, D., Pino, A., Pinto, V. L., Piras, S., Polistena, A., Portinari, M., Reina, S., Rotolo, G., Russo, G., Scalise, E., Sgaramella, L. I., Sibilla, M. G., Spinelli, S., Spoletini, D., Curto, L. S., Tascone, M., Torresan, F., Varaldo, E., Viviani, E., and Zucca, A.

Subjects
2019-20 coronavirus outbreak, medicine.medical_specialty, AcademicSubjects/MED00910, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), pandemics, NO, Pandemic, Research Letter, medicine, humans, Thyroid cancer, Thyroid Neoplasm, LS7_4, Thyroid Neoplasms, Thyroidectomy, SARS-CoV-2, COVID-19, Pandemics, Italy, business.industry, thyroid neoplasms, Retrospective cohort study, medicine.disease, Comorbidity, comorbidity, retrospective studies, thyroidectomy, Settore MED/18 - Chirurgia Generale, Emergency medicine, Surgery, AcademicSubjects/MED00010, business
Abstract

N/A

Published
2021

10. The social and economic cost of sleep disorders.

Author

Streatfeild J., Smith J., Mansfield D., Pezzullo L., Hillman D., Streatfeild J., Smith J., Mansfield D., Pezzullo L., and Hillman D.

Abstract

Study Objectives: To estimate economic cost of common sleep disorders in Australia for 2019-2020. Method(s): Costs were estimated for obstructive sleep apnea (OSA), insomnia, and restless legs syndrome (RLS) using prevalence, financial, and nonfinancial data from national databases. These included: (1) financial costs associated with health care, informal care, productivity losses, non-medical accident costs, deadweight loss from taxation/welfare inefficiencies; and (2) nonfinancial costs associated with loss of well-being. They were expressed in U.S. dollars ($). Result(s): Estimated overall cost of sleep disorders in Australia in 2019-2020 (population: 25.5 million) was $35.4 billion (OSA $13.1 billion; insomnia $13.3 billion, RLS $9.0 billion). Of this, the financial cost component was $10.0 billion, comprised of: health system costs $0.7 billion; productivity losses $7.7 billion; informal care $0.2 billion; other, mainly non-medical accident costs, $0.4 billion; and deadweight losses $1.0 billion. For moderate to severe OSA syndrome, insomnia unrelated to other conditions and RLS, financial costs represented $16,717, $21,982, and $16,624 per adult with the condition for the year, respectively. The nonfinancial cost was $25.4 billion. Conclusion(s): The economic costs associated with sleep disorders are substantial. The financial component of $10.0 billion is equivalent to 0.73% of Australian gross domestic product. The nonfinancial cost of $25.4 billion represents 3.2% of total Australian burden of disease for the year. Health system costs of these disorders are low relative to those associated with their consequences, suggesting greater expenditure on detection, treatment and prevention is warranted. Copyright © 2021 Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Published
2021

15. Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy

Author

Bellevicine C., Migliatico I., Sgariglia R., Nacchio M., Vigliar E., Pisapia P., Iaccarino A., Bruzzese D., Fonderico F., Salvatore D., Biondi B., Masone S., Novizio V., Scavuzzo F., Serino D., De Palma M., Chiofalo M. G., Botti G., Pezzullo L., Nuzzo V., Spiezia S., De Chiara G., Iorio S., Conzo G., Docimo G., Faggiano A., Bongiovanni M., Malapelle U., Colao A., Triassi M., Troncone G., Bellevicine, C., Migliatico, I., Sgariglia, R., Nacchio, M., Vigliar, E., Pisapia, P., Iaccarino, A., Bruzzese, D., Fonderico, F., Salvatore, D., Biondi, B., Masone, S., Novizio, V., Scavuzzo, F., Serino, D., De Palma, M., Chiofalo, M. G., Botti, G., Pezzullo, L., Nuzzo, V., Spiezia, S., De Chiara, G., Iorio, S., Conzo, G., Docimo, G., Faggiano, A., Bongiovanni, M., Malapelle, U., Colao, A., Triassi, M., and Troncone, G.

Subjects
Adult, Male, Adolescent, Carcinogenesis, Biopsy, Fine-Needle, Clinical Decision-Making, Thyroid Gland, Risk Assessment, 7-gene test, cancer, cytopathology, fine-needle aspiration, molecular diagnostics, thyroid, Diagnosis, Differential, Young Adult, Preoperative Care, Biomarkers, Tumor, Humans, Genetic Testing, Prospective Studies, Thyroid Nodule, Child, Aged, Aged, 80 and over, Patient Selection, molecular diagnostic, Middle Aged, Prognosis, Mutation, Thyroidectomy, Female
Abstract

Background: Thyroid fine-needle aspiration (FNA) is a reliable and cost-effective diagnostic tool for establishing the nature of thyroid nodules, although up to 30% of FNAs are still classified as "indeterminate." Molecular testing of FNAs could improve preoperative diagnosis, thereby reducing unnecessary surgery. In this multicenter prospective study the authors investigated, using a 7-gene assay, the distribution and diagnostic impact of BRAF, RAS, RET/PTC, and PAX8/PPARg, the most frequent genomic alterations occurring during thyroid oncogenesis. Methods: In total, of 1172 routine FNAs from 7 centers in southern Italy were classified according to the Bethesda System for Reporting Thyroid Cytopathology. Each specimen was tested, and molecular data were compared with available histology or cytologic follow-up. Results: In particular, for atypia of undetermined significance/follicular lesion of undetermined significance cases, the 7-gene test confirmed the high positive predictive value of BRAFV600E and BRAF-like mutations (80%) and the moderate positive predictive value of RAS-like alterations (32.4%), suggesting different surgical management, depending on the type of mutation. The rate of mutation-positive FNAs was strictly related to the risk of malignancy of each diagnostic class, supporting the identification of prognostically relevant diagnostic categories. Conclusions: The 7-gene panel test improves the preoperative risk stratification of indeterminate thyroid FNAs, especially when considering the biologic significance of the different types of mutations. Moreover, the rate of mutation-positive FNAs is related to the risk of malignancy of each diagnostic class. Keywords: 7-gene test; cancer; cytopathology; fine-needle aspiration; molecular diagnostics; thyroid.

Published
2019

23. Radioimmunotherapy with haemopoietic stem cell transplantation for treatment of malignant non-Hodgkin lymphoma: multicentre study on thirty patients

Author

Mele, A., Rana, A., De Francesco, R., Del Casale, C., Messa, A., Greco, G., Sibilla, S., Frusciante, V., Varraso, A., Milone, G., Leotta, S., Olivieri, A., Ciminiello, M., Mettivier, V., Pezzullo, L., Musso, M., Porretto, F., Iacopino, P., Console, G., Cascavilla, N., Scalzulli, P., Musto, P., Caputo, M., Ostuni, A., and Pavone, V.

Published
2008

30. Economic impact of delirium in Australia: A cost of illness study

Author

Pezzullo, L, Streatfeild, J, Hickson, J, Teodorczuk, A, Agar, MR, Caplan, GA, Pezzullo, L, Streatfeild, J, Hickson, J, Teodorczuk, A, Agar, MR, and Caplan, GA

Abstract

Objectives To estimate the economic impact of delirium in the Australian population in 2016-2017, including financial costs, and its burden on health. Design, setting and participants A cost of illness study was conducted for the Australian population in the 2016-2017 financial year. The prevalence of delirium in 2016-2017 was calculated to inform cost estimations. The costs estimated in this study also include dementia attributable to delirium. Main outcome measures The total and per capita costs were analysed for three categories: health systems costs, other financial costs including productivity losses and informal care and cost associated with loss of well-being (burden of disease). Costs were expressed in 2016-2017 pound sterling (£) and Australian dollars (A). Results There were an estimated 132 595 occurrences of delirium in 2016-2017, and more than 900 deaths were attributed to delirium in 2016-2017. Delirium causes an estimated 10.6% of dementia in Australia. The total costs of delirium in Australia were estimated to be £4.3 billion (A8.8 billion) in 2016-2017, ranging between £2.6 billion (A5.3 billion) and £5.9 billion (A12.1 billion). The total estimated costs comprised financial costs of £1.7 billion and the value of healthy life lost of £2.5 billion. Dementia attributable to delirium accounted for £2.2 billion of the total cost of delirium. Conclusions These findings highlight the substantial burden that delirium imposes on Australian society - both in terms of financial costs associated with health system expenditure and the increased need for residential aged care due to the functional and cognitive decline associated with delirium and dementia. To reduce the substantial well-being costs of delirium, further research should seek to better understand the potential pathways from an episode of delirium to subsequent mortality and reduced cognitive functioning outcomes.

Published
2019

34. PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES

Author

Le Pen, C., primary, Fricke, F.U., additional, Newsome, P., additional, Schattenberg, J.M., additional, Serfaty, L., additional, Aghemo, A., additional, Augustin, S., additional, Tsochatzis, E., additional, Canbay, A., additional, de Lédinghen, V., additional, Bugianesi, E., additional, Romero-Gomez, M., additional, Ryder, S., additional, Bantel, H., additional, Boursier, J., additional, Petta, S., additional, Crespo, J., additional, Castera, L., additional, Leroy, V., additional, Elliott, R.A., additional, Atella, V., additional, Mestre-Ferrandiz, J., additional, Floros, L., additional, Torbica, A., additional, Morgan, A., additional, Hartmanis, S., additional, Trylesinski, A., additional, Cure, S., additional, Stirzaker, E., additional, Vasudevan, S., additional, Pezzullo, L., additional, and Ratziu, V., additional

Published
2019
Full Text
View/download PDF

35. INCREASED CYTOMEGALOVIRUS (CMV) REACTIVATION IN PATIENTS TREATED WITH BENDAMUSTINE BASED REGIMEN IS CORRELATE WITH DRAMATICAL REDUCTION OF CD4+ T LYMPHOCITES

Author

Pezzullo, L., primary, Bruno, A., additional, Cassiodoro, G., additional, Bianco, R., additional, Villani, G., additional, Vaccaro, E., additional, Rosamilio, R., additional, Martorelli, M., additional, Fontana, R., additional, Guariglia, R., additional, Serio, B., additional, and Selleri, C., additional

Published
2019
Full Text
View/download PDF

38. Germline polymorphisms of the VEGF-pathway predict recurrence in non-advanced differentiated thyroid cancer

Author

Marotta V, Sciammarella C, Mario Capasso, Testori A, Pivonello C, Mg, Chiofalo, Gambardella C, Grasso M, Antonino A, Annunziata A, Pe, Macchia, Pivonello R, Santini L, Botti G, Losito S, Pezzullo L, Colao A, Faggiano A, Marotta, V, Sciammarella, C, Capasso, M, Testori, A, Pivonello, C, Chiofalo, Mg, Gambardella, C, Grasso, M, Antonino, A, Annunziata, A, Macchia, Pe, Pivonello, R, Santini, L, Botti, G, Losito, S, Pezzullo, L, Colao, A, and Faggiano, A.

Published
2016

39. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies

Author

Pacini, F., Basolo, F., Bellantone, Rocco Domenico Alfonso, Boni, G., Cannizzaro, M. A., De Palma, M., Durante, C., Elisei, R., Fadda, Guido, Frasoldati, A., Fugazzola, L., Guglielmi, Rinaldo, Lombardi, Celestino Pio, Miccoli, P., Papini, Enrico, Pellegriti, G., Pezzullo, L., Pontecorvi, Alfredo, Salvatori, Massimo, Seregni, E., Vitti, P., Bellantone, R. (ORCID:0000-0002-0844-3469), Fadda, G. (ORCID:0000-0003-2013-7293), Guglielmi, R., Lombardi, C. P. (ORCID:0000-0001-8910-6693), Papini, E., Pontecorvi, A. (ORCID:0000-0003-0570-6865), Salvatori, M. (ORCID:0000-0003-0208-1273), Pacini, F., Basolo, F., Bellantone, Rocco Domenico Alfonso, Boni, G., Cannizzaro, M. A., De Palma, M., Durante, C., Elisei, R., Fadda, Guido, Frasoldati, A., Fugazzola, L., Guglielmi, Rinaldo, Lombardi, Celestino Pio, Miccoli, P., Papini, Enrico, Pellegriti, G., Pezzullo, L., Pontecorvi, Alfredo, Salvatori, Massimo, Seregni, E., Vitti, P., Bellantone, R. (ORCID:0000-0002-0844-3469), Fadda, G. (ORCID:0000-0003-2013-7293), Guglielmi, R., Lombardi, C. P. (ORCID:0000-0001-8910-6693), Papini, E., Pontecorvi, A. (ORCID:0000-0003-0570-6865), and Salvatori, M. (ORCID:0000-0003-0208-1273)

Abstract

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Methods: Six scientific Italian societies entitled to cure thyroid cancer patients (the Italian Thyroid Association, the Medical Endocrinology Association, the Italian Society of Endocrinology, the Italian Association of Nuclear Medicine and Molecular Imaging, the Italian Society of Unified Endocrine Surgery and the Italian Society of Anatomic Pathology and Diagnostic Cytology) felt the need to develop a consensus report based on significant scientific advances occurred in the field. Objective: The document includes recommendations regarding initial evaluation of thyroid nodules, clinical and ultrasound criteria for fine-needle aspiration biopsy, initial management of thyroid cancer including staging and risk assessment, surgical management, radioiodine remnant ablation, and levothyroxine therapy, short-term and long-term follow-up strategies, and management of recurrent and metastatic disease. The objective of this consensus is to inform clinicians, patients, researchers, and health policy makers about the best strategies (and their limitations) relating to the diagnosis and treatment of differentiated thyroid cancer.

Published
2018

42. Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies

Author

Pacini, F., primary, Basolo, F., additional, Bellantone, R., additional, Boni, G., additional, Cannizzaro, M. A., additional, De Palma, M., additional, Durante, C., additional, Elisei, R., additional, Fadda, G., additional, Frasoldati, A., additional, Fugazzola, L., additional, Guglielmi, R., additional, Lombardi, C. P., additional, Miccoli, P., additional, Papini, E., additional, Pellegriti, G., additional, Pezzullo, L., additional, Pontecorvi, A., additional, Salvatori, M., additional, Seregni, E., additional, and Vitti, P., additional

Published
2018
Full Text
View/download PDF

43. Cost-effectiveness of screening for bowel cancer: Increasing bowel cancer testing rates through a general practitioner-organised health care package would reduce incidence and prove cost-effective.

Author

Creelman D.G., Bolin T.D., Korman M.G., Nicholson F., Pezzullo L., Engelman J., Collings K., Creelman D.G., Bolin T.D., Korman M.G., Nicholson F., Pezzullo L., Engelman J., and Collings K.

Abstract

Treating bowel cancer is expensive, and the cost is rising rapidly. In the past decade, costs have increased for treating cancers at all stages (in particular, Stages 3 and 4), largely due to increased chemotherapy options and the introduction of more effective but expensive drug regimens.1 Increased treatment costs are a stimulus for the considerable effort in the areas of prevention and early detection.Copyright © 2016 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved.

Published
2017

46. Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment

Author

Rosamilio R, Valentina Giudice, Ferrara I, Annunziata S, Pezzullo L, Villani G, Baldi C, Guariglia R, Rocco M, and Selleri C

Subjects
LGL leukemia, Bendamustine, LGL leukemia, bendamustine, chemotherapy, salvage therapy, immunosuppression, Chemotherapy, Salvage therapy, Articles, Immunosuppression
Abstract

T-large granular lymphocyte leukemia (T-LGLL) is a chronic clonal proliferation of effector memory cytotoxic CD3+CD57+CD56− T cells and the current guidelines suggest immunosuppressive therapy as first-line therapy, but the treatment of refractory/relapsed patients is still challenging due to the lack of prospective studies. We describe a series of two refractory/relapsed T-LGLL patients successfully treated with bendamustine, a chemotherapeutic agent largely used for B-cell neoplasms, but poorly investigated for the treatment of T-cell diseases. Complete remission (CR) was achieved in 3 and 6 months, respectively, and maintained for at least 20 months. One patient relapsed after a 20-month CR, but she was responsive to bendamustine therapy again, obtaining a further prolonged CR. Bendamustine as single agent or in combination could be a feasible therapeutic option in refractory/relapsed T-LGLL, especially for elderly patients because of its safety profile.

Published
2016
Full Text
View/download PDF

48. TIXAGEVIMAB‐CILGAVIMAB THERAPY IN THE PREVENTION OF SARS‐COV2 INFECTION IN NON HODGKIN‐B LYMPHOMAS AND HODGKIN LYMPHOMAS UNDER TREATMENT: OUR EXPERIENCE.

Author

Pezzullo, L., Giudice, V., D'Addona, M., Buonanno, M. T., De Novellis, D., Ferrara, I., Fontana, R., Guariglia, R., Luponio, S., Martorelli, M. C., Mettivier, L., Serio, B., and Selleri, C.

Subjects
SARS-CoV-2, INFECTION prevention
Abstract

Patients with B-cell malignancies who become infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are at an increased risk of morbidity and mortality due to advanced age, use of B-cell-depleting therapies, and immunodeficiency. In 9/21 pts (43%) the treatment was not interrupted (4 patients in induction therapy and 5 patients in maintenance therapy) all with mild COVID symptoms, no COVID-related complication was documented in these patient. Of the patients who died, 1 had finished induction therapy (R-BAC) while 5 were on maintenance therapy (3 rituximab and 2 obinutuzumab). [Extracted from the article]

Published
2023
Full Text
View/download PDF

49. CLINICAL OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH DELETION AND INSERTION EVENTS (DI) IN THE TYROSINE KINASE DOMAIN OF BCR-ABL

Author

Peluso AL, Seneca E, Cosenza MR, Musella F, Cacciapuoti V, Esposito N, Muccioli Casadei G, Pisano I, De Angelis B, Annunziata M, Sessa U, Nunziata G, Palmieri F, Palmieri R, Danise P, Pezzullo L, Serio B, Esposito MR, Villa MR, Spiezia M, Vallone R, De Falco G, Sica A, Camera A, Iovine M, Svanera L, Soverini S, Martinelli G, Luciano L, QUINTARELLI, CONCETTA, IZZO, BARBARA, PANE, FABRIZIO, Peluso AL, Peluso, Al, Quintarelli, Concetta, Seneca, E, Cosenza, Mr, Musella, F, Cacciapuoti, V, Esposito, N, Izzo, Barbara, Muccioli Casadei, G, Pisano, I, De Angelis, B, Annunziata, M, Sessa, U, Nunziata, G, Palmieri, F, Palmieri, R, Danise, P, Pezzullo, L, Serio, B, Esposito, Mr, Villa, Mr, Spiezia, M, Vallone, R, De Falco, G, Sica, A, Camera, A, Iovine, M, Svanera, L, Soverini, S, Martinelli, G, Luciano, L, and Pane, Fabrizio

Published
2013

50. OPSI threat in hematological patients

Author

Serio B, Pezzullo L, Valentina Giudice, Fontana R, Annunziata S, Ferrara I, Rosamilio R, De Luca C, Rocco M, Montuori N, Selleri C, Serio, B, Pezzullo, L, Giudice, V, Fontana, R, Annunziata, S, Ferrara, I, Rosamilio, R, De Luca, C, Rocco, M, Montuori, Nunzia, and Selleri, C.

Subjects
sepsis, hematological disorders, Hematological disorders, OPSI, Splenectomy, Articles, Overwhelming postsplenectomy infection (OPSI) syndrome, splenectomy
Abstract

Overwhelming post-splenectomy infection (OPSI) is a rare medical emergency, mainly caused by encapsulated bacteria, shortly progressing from a mild flu-like syndrome to a fulminant, potentially fatal, sepsis. The risk of OPSI is higher in children and in patients with underlying benign or malignant hematological disorders. We retrospectively assessed OPSI magnitude in a high risk cohort of 162 adult splenectomized patients with malignant (19%) and non malignant (81%) hematological diseases, over a 25-year period: 59 of them splenectomized after immunization against encapsulated bacteria, and 103, splenectomized in the previous 12-year study, receiving only life-long oral penicillin prophylaxis. The influence of splenectomy on the immune system, as well as the incidence, diagnosis, risk factors, preventive measures and management of OPSI are also outlined. OPSI occurred in 7 patients (4%) with a median age of 37 years at time interval from splenectomy ranging from 10 days to 12 years. All OPSIs occurred in non immunized patients, except one fatal Staphylococcus aureus -mediated OPSI in a patient adequately immunized before splenectomy. Our analysis further provides evidence that OPSI is a lifelong risk and that current immune prophylaxis significantly decreases OPSI development. Improvement in patients' education about long-term risk of OPSI and increased physician awareness to face a potentially lethal medical emergency, according to the current surviving sepsis guidelines, represent mandatory strategies for preventing and managing OPSI appropriately.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results